Q2 2026 Earnings Presentation

July 29, 2026

Forward-Looking Statements

This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles in the United States (GAAP). The Company analyzes net sales on a constant currency basis, organic basis, and organic constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share, including its components, as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated statements of income.

CONMED Vision

Empower healthcare providers worldwide to deliver exceptional outcomes for patients.

Focus behind the Vision

People, Products, Profitability

WE DO
things the right way.

WE MAKE
and keep commitments.

WE OPERATE
with urgency.

WE BELIEVE
in the power of engaged talent.

WE DELIVER
exceptional results.

Financial Performance Q2 2026







Worldwide CC Revenue Growth[1]



CC Revenue Growth[1]



Worldwide CC Revenue Growth[1]



Revenue

$343.5M

0.3% vs. Q2 2025 as reported
-0.5% vs. Q2 2025 constant currency
6.0% vs. Q2 2025 organic constant currency[3]

Diluted EPS

$0.77

11.6% vs. Q2 2025

Adjusted Diluted Net EPS[2]

$1.38

20.0% vs. Q2 2025

(1) Growth rates shown versus the three months ended June 30, 2025 in constant currency. The reconciliation to GAAP numbers is included in our earnings release issued on July 29, 2026.
(2) Adjusted diluted EPS excludes the costs of special items, including charges for operational optimization costs, product rationalization costs, loss on sale of product offering, EU medical device regulations (MDR), gain on early extinguishment of debt (net), contingent consideration, gain on sale of product offering, legal matters, and amortization of intangible assets and deferred financing fees, net of tax.
(3) Growth rates shown versus the three months ended June 30, 2025 in organic constant currency. The reconciliation to GAAP numbers is included in our earnings release issued on July 29, 2026.

CONMED

Financial Performance YTD 2026







Worldwide CC Revenue Growth[1]



CC Revenue Growth[1]



Worldwide CC Revenue Growth[1]



Revenue

$660.5M

-0.5% vs. Q2 2025 as reported
-1.7% vs. Q2 2025 constant currency
4.1% vs. Q2 2025 organic constant currency[3]

Diluted EPS

$1.22

38.6% vs. Q2 2025

Adjusted Diluted EPS[2]

$2.27

8.6% vs. Q2 2025

(1) Growth rates shown versus the six months ended June 30, 2025 in constant currency. The reconciliation to GAAP numbers is included in our earnings release issued on July 29, 2026.
(2) Adjusted diluted EPS excludes the costs of special items, including charges for operational optimization costs, product rationalization costs, loss on sale of product offering, EU medical device regulations (MDR), executive transition costs, contingent consideration, gain on early extinguishment of debt (net), termination of distribution agreement, gain on sale of product offering, legal matters, and amortization of intangible assets and deferred financing fees, net of tax.
(3) Growth rates shown versus the six months ended June 30, 2025 in organic constant currency. The reconciliation to GAAP numbers is included in our earnings release issued on July 29, 2026.

2026 Financial Guidance Update

	Twelve Months Ending December 31, 2026			
Dollars in millions, except per share figures *Percentages on a year-over-year basis*	**Updated Financial Guidance**		**Prior Financial Guidance[3]**	
	Low	**High**	**Low**	**High**
Net Sales (GAAP)	**$1,358**	**$1,373**	**$1,350**	**$1,375**
Net Sales Growth, as reported	(1.2)%	(0.1)%	(1.8)%	0.0%
Estimated impact of foreign currency exchange rate fluctuations	(0.5)%	(0.5)%	(0.3)%	(0.5)%
Net Sales Growth, Constant Currency	(1.7)%	(0.7)%	(2.1)%	(0.5)%
Estimated impact of strategic product line exits[1]	6.7%	6.7%	7.1%	7.0%
Net Sales Growth, Organic, Constant Currency	5.0%	6.0%	5.0%	6.5%
Adjusted Diluted Net EPS[2]	**$4.48**	**$4.60**	**$4.30**	**$4.45**
Adjusted Diluted Net EPS Growth	(2.4)%	0.2%	(6.3%)	(3.1%)

[1] Organic constant currency revenue excludes the sales of certain gastroenterology ("GI") product offerings for the three and six months ended June 30, 2026 and 2025, and twelve months ending December 31, 2026 and 2025, related to the Company's previously announced strategic exits as part of its portfolio optimization strategy.
[2] Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
[3] "Prior financial guidance" reflects the Company's full year 2026 financial guidance, previously updated on April 29, 2026.

CONMED Driven to Win

- **Leveraging Growth Drivers**
  Focusing on high-growth, high-margin products: AirSeal, Buffalo Filter, BioBrace

- **Optimizing Portfolio**
  Exiting gastroenterology to align resources with minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair

- **Transforming Supply Chain**
  Driving supply chain transformation focused on resiliency, predictability, scalability, and efficiency

- **Strengthening Balance Sheet**
  Enhancing balance sheet to drive growth and shareholder returns

Environmental, Social and Governance

Together we are making a difference for a better tomorrow

View CONMED's full 2024 ESG Report on CONMED.com

Environmental

CONMED manufacturing operations have recycling programs including eScrap, metal, cardboard, plastic, and paper.

Use of ISO 14001 and 45001 as a framework to harmonize an Environmental Management System across CONMED.

Development of capabilities to measure and understand greenhouse gas emissions associated with our operations, and to identify areas of high impact and opportunities for reduction.

Social

Partners with the United Way to serve communities where we operate in the U.S.

98% of employees participated in the Gallup Q12 Employee Engagement Survey.

Committed to maintaining a quality system that provides safe and effective products and services that meet the needs and requirements of our patients, customers, company stakeholders and all regulatory requirements.

Governance

In addition to oversight by the full Board, the ESG Steering Committee provides strategic direction and prioritization of ESG initiatives.

CONMED's executive leadership is responsible for setting the ethical code and overseeing compliance.

Effective board leadership and independent oversight. 100% independent standing board committees and regular executive sessions of independent directors.